From Nasdaq.: 2025-05-13 08:59:00

HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc., has agreed to purchase the Kadima Neuropsychiatry Institute in California. The financial details of the transaction have not been disclosed. Kadima Neuropsychiatry will become a clinical model for Hope’s treatment offerings nationwide, including psychedelic medications, transcranial magnetic stimulation, and hyperbaric therapy. David Feifel, Founder and Medical Director of Kadima, will join HOPE as its first Chief Medical Innovation Officer. The deal is expected to be accretive to revenue and EBITDA for NRx and HOPE. NRx’s stock is trading at $2.02, down 2.88 percent in pre-market hours on the Nasdaq.



Read more at Nasdaq.: HOPE Therapeutics To Buy Kadima Neuropsychiatry Institute For Undisclosed Sum